- Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
- Recursion to Participate in Upcoming Investor Conferences
- Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
- Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
- Recursion to Participate in Upcoming Investor Conference
- Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 11.72, 138.21% above the 52 week low of 4.92 set on May 12, 2022.
4.92May 12 202221.98Oct 06 2021
Markit short selling activity
|Market cap||1.84bn USD|
|EPS (TTM)||-1.37 |
Data delayed at least 15 minutes, as of Oct 06 2022 21:00 BST.